Coherus BioSciences, Inc. (NASDAQ:CHRS) Short Interest Update

Coherus BioSciences, Inc. (NASDAQ:CHRS) saw a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 30,720,000 shares, a decrease of 7.0% from the November 15th total of 33,040,000 shares. Based on an average daily volume of 5,120,000 shares, the short-interest ratio is presently 6.0 days.

Institutional Investors Weigh In On Coherus BioSciences

Several institutional investors and hedge funds have recently modified their holdings of CHRS. Nisa Investment Advisors LLC increased its stake in Coherus BioSciences by 2,672.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 20,657 shares of the biotechnology company’s stock worth $36,000 after buying an additional 19,912 shares during the period. Systematic Financial Management LP acquired a new position in shares of Coherus BioSciences in the 3rd quarter valued at approximately $28,000. TIAA Trust National Association purchased a new position in shares of Coherus BioSciences during the 2nd quarter valued at approximately $47,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Coherus BioSciences by 32.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 30,851 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 7,608 shares during the last quarter. Finally, Hsbc Holdings PLC increased its stake in shares of Coherus BioSciences by 10.6% in the second quarter. Hsbc Holdings PLC now owns 103,183 shares of the biotechnology company’s stock worth $179,000 after buying an additional 9,905 shares during the last quarter. Hedge funds and other institutional investors own 72.82% of the company’s stock.

Coherus BioSciences Stock Performance

Shares of NASDAQ:CHRS traded down $0.05 during midday trading on Tuesday, hitting $1.65. 1,382,756 shares of the company’s stock traded hands, compared to its average volume of 3,302,316. The firm’s fifty day moving average price is $1.06 and its two-hundred day moving average price is $1.30. Coherus BioSciences has a twelve month low of $0.66 and a twelve month high of $3.70. The company has a market cap of $190.10 million, a PE ratio of -21.25 and a beta of 0.86.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on CHRS shares. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Coherus BioSciences in a research report on Wednesday, December 4th. StockNews.com downgraded shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 19th. Finally, Robert W. Baird boosted their target price on shares of Coherus BioSciences from $4.00 to $6.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.38.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.